By Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)
The Medicinal Chemistry and Synthesis (MCS) Group of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), based in Barcelona, is seeking to contract a company specialized in regulatory affairs to prepare a regulatory roadmap aimed at the development of new therapies for which no clearly established regulatory precedents exist. The selected entity will be responsible for defining a regulatory strategy and roadmap for photopharmacology, an innovative therapeutic platform based on controlling drug activity through light stimuli. Due to its innovative nature and the lack of clearly established regulatory precedents for this type of technology, it is necessary to define a specific regulatory strategy to guide its development. The scope of the service will include, among other aspects: - Preparation of a Regulatory Roadmap for the development of photopharmacology-based therapies. - Identification of regulatory requirements for non-clinical and clinical development through to the first study in humans (First-in-Human, FIH). Interested companies or professional service providers should submit a technical and financial proposal by 20 September 2026 to the following email address: ramona.galatola@iqac.csic.es Demonstrable experience in regulatory strategy, interaction with regulatory agencies, and the development of innovative therapies or advanced healthcare technologies will be valued. Deadline: 20th September 2026
